In last trading session, PDS Biotechnology Corporation (NASDAQ:PDSB) saw 0.31 million shares changing hands with its beta currently measuring 1.95. Company’s recent per share price level of $3.29 trading at $0.01 or 0.30% at ring of the bell on the day assigns it a market valuation of $121.14M. That closing price of PDSB’s stock is at a discount of -108.21% from its 52-week high price of $6.85 and is indicating a premium of 23.1% from its 52-week low price of $2.53. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.36 million shares which gives us an average trading volume of 306.62K if we extend that period to 3-months.
For PDS Biotechnology Corporation (PDSB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PDS Biotechnology Corporation (NASDAQ:PDSB) trade information
Upright in the green during last session for gaining 0.30%, in the last five days PDSB remained trading in the green while hitting it’s week-highest on Wednesday, 11/06/24 when the stock touched $3.29 price level, adding 2.37% to its value on the day. PDS Biotechnology Corporation’s shares saw a change of -33.80% in year-to-date performance and have moved 2.81% in past 5-day. PDS Biotechnology Corporation (NASDAQ:PDSB) showed a performance of -0.60% in past 30-days. Number of shares sold short was 4.8 million shares which calculate 12.15 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 9 to the stock, which implies a rise of 63.44% to its current value. Analysts have been projecting 9 as a low price target for the stock while placing it at a high target of 9. It follows that stock’s current price would drop -173.56% in reaching the projected high whereas dropping to the targeted low would mean a loss of -173.56% for stock’s current value.
PDS Biotechnology Corporation (PDSB) estimates and forecasts
Statistics highlight that PDS Biotechnology Corporation is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -6.27% of value to its shares in past 6 months, showing an annual growth rate of 10.79% while that of industry is 16.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 42.97% during past 5 years.
PDS Biotechnology Corporation (NASDAQ:PDSB)’s Major holders
Insiders are in possession of 3.99% of company’s total shares while institution are holding 14.98 percent of that, with stock having share float percentage of 15.60%. Investors also watch the number of corporate investors in a company very closely, which is 14.98% institutions for PDS Biotechnology Corporation that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at PDSB for having 1.41 million shares of worth $4.13 million. And as of 2024-06-30, it was holding 4.0465 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 0.49 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.3987 of outstanding shares, having a total worth of $1.43 million.
